HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is taking innovative and unique approaches to the diagnosis and treatment of Alzheimer’s disease. It is widely recognized that new methods of treating and diagnosing Alzheimer’s disease are urgently needed in the face of an impending world-wide epidemic of Alzheimer’s disease. Currently, an estimated 4.5 million Americans and more than 15 million people around the world suffer from the disease. By 2050, this number is expected to triple, creating enormous burdens on health-care systems, care-givers and communities.
